GLP-1 RAs: Evidence-Based Prescribing vs. The Compounded Peptide Crisis

Endocrinology / Obesity 1 source · Updated Aug 4, 2026

Navigating legitimate GLP-1 RA controversies alongside the safety crisis in compounded and unregulated peptide products.

Bottom Line

FDA-approved GLP-1 RAs are evidence-based, disease-modifying medications, but pharmacists must also address the parallel crisis of compounded semaglutide and unregulated peptide products that pose serious safety risks to patients.

State of Play

GLP-1 receptor agonists have become the most prescribed new drug class in a generation, driven by cardiovascular and weight outcomes data. Simultaneously, a parallel market of compounded semaglutide and unregulated peptide products has emerged, creating patient safety concerns.

Evidence at a Glance

Source	Key finding	Grade / Verdict
GLP-1 RAs: Evidence-Based Prescribing vs. The Compounded Peptide Crisis Study · PharmD Signal Reference Card	—

🔒

Practice Recommendations: Subscribers Only

The bedside actions and open questions that turn this evidence into practice.

Practice Considerations: the bedside actions

Open Questions & evidence gaps

Want the full review?

Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.

Become a Subscriber →

reference-card

🎓

Synthesized and reviewed by a licensed pharmacist

Each topic review is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Hot Topics